bevacizumab (Avastin)

following a full submission considered under the end of life and ultra orphan medicine process

bevacizumab (Avastin®) is accepted for restricted use within NHS Scotland.

Indication under review: in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Restriction: for use in combination with cisplatin and paclitaxel.

In an open-label, randomised, phase III study, the addition of bevacizumab to combination chemotherapy increased overall survival.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of bevacizumab. This advice is contingent upon the continuing availability of the patient
access scheme in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician and Engagement (PACE) meeting.